InflaRx マネジメント

マネジメント基準チェック /24

InflaRxの CEO はNiels Riedemannで、 Jan2007年に任命され、の在任期間は 17.83年です。は、会社の株式の1.82%を直接所有しており、その価値は€ 2.43M 。経営陣と取締役会の平均在任期間はそれぞれ3.9年と5.5年です。

主要情報

Niels Riedemann

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	17.8yrs
CEOの所有権	1.8%
経営陣の平均在職期間	3.9yrs
取締役会の平均在任期間	5.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Niels Riedemann (51 yo)

17.8yrs

在職期間

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. Dr. Riedemann founded InflaRx N.V. in 2007 as InflaRx GmbH. Dr. Riedemann spen...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Niels Riedemann	Co-Founder	17.8yrs	データなし	1.82% € 2.4m
Renfeng Guo	Co-Founder	17.8yrs	データなし	2.99% € 4.0m
Thomas Taapken	Chief Financial Officer	4.1yrs	データなし	0.0059% € 8.0k
Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance	1.6yrs	データなし	データなし
Camilla Chong	Chief Medical Officer	1.3yrs	データなし	データなし
Jan Medina	Head of Investor Relations & VP	less than a year	データなし	データなし
Christian Schmid	VP and Head of Legal Affairs & General Counsel	no data	データなし	データなし
Nicole Bertsch	Senior Director & Head of Human Resources	3.7yrs	データなし	データなし
Maria Habel	VP, Head of Preclinical R&D and QC	11.8yrs	データなし	データなし
Bruce Burnett	VP & Head of Medical Affairs	no data	データなし	データなし
Kofi Boaten	Senior Director and Head of Supply Quality & Clinical Trial Supplies	no data	データなし	データなし
Peter Hurt	Senior Director and Head of Drug Safety & Pharmacovigiliance	no data	データなし	データなし

3.9yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: IF0の経営陣は経験豊富であると考えられます ( 3.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Niels Riedemann	Co-Founder	no data	データなし	1.82% € 2.4m
Renfeng Guo	Co-Founder	no data	データなし	2.99% € 4.0m
Nicolas Fulpius	Independent Chairman of the Board	17.8yrs	データなし	0.79% € 1.1m
K. Reinhart	Member of Scientific Advisory Board	no data	データなし	データなし
P. Ward	Member of Scientific Advisory Board	no data	データなし	データなし
Richard Brudnick	Independent Non-Executive Director	5.5yrs	データなし	0.085% € 113.7k
Hege Hellstrom	Non-Executive Director	1.6yrs	データなし	データなし
Mark Kubler	Independent Non-Executive Director	9.8yrs	データなし	1.63% € 2.2m
Anthony Gibney	Independent Non-Executive Director	3.5yrs	データなし	0.017% € 22.7k

5.5yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: IF0の取締役会は経験豊富であると考えられます ( 5.5年の平均在任期間)。

InflaRx マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

InflaRx N.V., Annual General Meeting, Apr 25, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

InflaRx N.V., Annual General Meeting, Apr 28, 2022

InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer

Recent updates

InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

InflaRx N.V. to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Revenue and earnings growth

InflaRx N.V. to Report Q2, 2024 Results on Aug 08, 2024

Inflarx’S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (Ards)

InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904

InflaRx N.V. to Report Q1, 2024 Results on May 08, 2024

InflaRx N.V., Annual General Meeting, Apr 25, 2024

No longer forecast to breakeven

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. to Report Q4, 2023 Results on Mar 21, 2024

InflaRx N.V. Appoints Jan Medina as Head of Investor Relations

InflaRx N.V. Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

New major risk - Financial position

New minor risk - Market cap size

InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Inflarx N.V.'S Marketing Authorization Application (Maa) for Vilobelimab for Treatment of Critically Ill Covid-19 Patients Under Review by European Medicines Agency (Ema)

Forecast breakeven date moved forward to 2024

New major risk - Share price stability

Forecast breakeven date moved forward to 2024

Inflarx N.V. Appoints Camilla Chong as Chief Medical Officer, Effective July 1, 2023

Forecast to breakeven in 2025

InflaRx N.V. Announces Details Related to the Design of its Planned Phase III Study with Vilobelimab in Ulcerative PG

InflaRx N.V. Provides Update on Planned Phase Iii Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of Its Eua Application in Critically Ill Covid-19 Patients

InflaRx N.V. announced that it expects to receive $2.5 million in funding from Staidson (Beijing) BioPharmaceuticals Co., Ltd.

InflaRx N.V. Initiates First-In-Human Study with Small Molecule C5ar Inhibitor Inf904

Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx N.V. Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in the Lancet Respiratory Medicine

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically III COVID-19 Patients

InflaRx Receives U.S. Food and Drug Administration Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx N.V. Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

No longer forecast to breakeven

Forecast to breakeven in 2024

InflaRx N.V., Annual General Meeting, Apr 28, 2022

InflaRx N.V. Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Forecast to breakeven in 2024

InflaRx N.V. Reports That It Has Received an Advice Letter from the U.S. Food and Drug Administration Related to Its Phase Iii Program with Vilobelimab

InflaRx N.V. Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma

InflaRx N.V Announces New Pipeline Program – Oral C5aR Inhibitor

InflaRx N.V. Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

Independent Non-Executive Director Lina Ma has left the company

InflaRx N.V. to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

Inflarx Doses First Patient in Multicenter Phase Ii Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

Inflarx Announces Positive Topline Results for Vilobelimab from the U.S. Phase Ii Anca-Associated Vasculitis Ixplore Study

New 90-day high: €5.29

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

Inflarx Provides an Update on the Ongoing Development of Vilobelimab (Ifx-1), First-In-Class Anti-C5a Antibody

New 90-day high: €4.60

InflaRx N.V. Completes Enrollment in Vilobelimab (Ifx-1) European Phase Ii Study in Anca-Associated Vasculitis

InflaRx N.V. Promotes Jordan Zwick to Chief Strategy Officer

New 90-day low - €3.04

New 90-day low - €3.46

New 90-day low - €3.98

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24